A neuro-invasive infection is commonly presented when a pathogenic bacterium, virus, fungi, or parasite spreads through the bloodstream and reaches the spinal cord or the brain. In the brain and spinal cord, the causative organism sets up in the fluids or linings of these organs and starts developing into a more serious and advanced infection. Various euro-invasive infections such as the West Nile disease are highly fatal. West Nile disease is transmitted to people through infected mosquito bites. The common types of inflammations that are the result of neuro-invasive infections include meningitis and encephalitis.
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
- However, with COVID-19, the supply chain of the raw materials required to manufacture drugs for neuro-invasive infections has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining as the manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the neuro-invasive infection market.
Top Impacting Factors
The increased prevalence of meningitis all over the world is one of the factors contributing to the growth of the neuro-invasive infection market. Meningitis can be caused by different pathogens, which include viruses, bacteria, and fungi.
In addition, pathogenic meningitis is highly communicable, which means that it can easily spread from one person to another. This has further led to the growth of the neuro-invasive infection market.
Encephalitis is another condition that leads to the inflammation of the brain tissue. It is often caused by viruses such as herpes simplex viruses, varicella-zoster virus, and possibly Zika virus. The increased spread of these viruses especially in the regions of Africa is another factor boosting the growth of the neuro-invasive infection market.
However, the lack of distribution channels and availability of diagnostic tests for different pathogens that may cause a neuro-invasive infection are some of the factors impeding the growth of the market.
Key Market Trends
- In many cases, encephalitis and meningitis can occur together in an individual leading to the increased chances of neuro-invasive infections. This trend is being noticed in regions facing epidemics of encephalitis.
- North America is anticipated to lead the neuro-invasive infection market followed by Europe, owing to increase in prevalence of neuro-invasive infections in these regions and rise in demand for technologically advanced treatment equipment.
- Asia-Pacific is expected to show remarkable growth in the neuro-invasive infection market. This can be attributed to the region's fast-paced healthcare infrastructure development and rise in awareness regarding neuro-invasive infections.
- Key players of the neuro-invasive infection market are focused on developing advanced diagnostic kits that rapidly help determine the causative organisms behind a neuro-invasive infection.
Key Benefits of the Report
- This study presents the analytical depiction of the neuro-invasive infection industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the neuro-invasive infection market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Neuro-invasive Infection Report
- Which are the leading players active in the neuro-invasive infection market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for neuro-invasive infection in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
- What are the impacts of COVID-19 on the industry?
- What is neuro-invasive infection?
- What are the current and predicted trends of the market?
Neuro-invasive Infection Market Report Highlights
Key Market Players
Heritage Pharma,, GlaxoSmithKline,, Pfizer Inc.,, Zydus Cadila, Inc., Bavarian Nordic A/S,, Plc.,, Teva Pharmaceutical Industries Ltd.,, Mylan N.V.,